Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 151 - 200 out of 6,616

Document Document Title
WO/2017/125093A1
Disclosed are a hydroquinone compound, a preparation method therefor, and an application in tumour resistance or immunomodulation. The structural formula of the hydroquinone compound is as shown in formula I, wherein: X is C=O or CH2; Y ...  
WO/2017/122209A2
Disclosed herein are compounds capable of inhibiting dimerization of NF-κB, for example, p65-p65 homodimerization and/or p50-p65 heterodimerization, the compounds being represented by formula I: X-L2-L1-L'2-Y Formula I wherein X, Y, L1,...  
WO/2017/114052A1
Disclosed are a high stress resistant plant growth regulator and a preparation method and use thereof. In particular, the compound provided by the present invention is an ABA substitute for significantly improving the stress resistance o...  
WO/2017/116558A1
The present invention relates to compounds that inhibit LSD1 activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and ...  
WO/2017/108152A1
The present invention relates to compounds according to formula (I), which are suitable for use in electronic devices, preferably organic electroluminescent devices.  
WO/2017/109095A1
The invention relates to (hetero) cyclic compounds as S1P modulators, pharmaceutical compositions comprising such compounds, and uses thereof in the treatment, alleviation or prevention of diseases or disorders mediated by an S1P receptor.  
WO/2017/102063A1
The present invention relates to compounds of the formula (1) which are suitable for use in electronic devices, in particular organic electroluminescent devices, and to electronic devices which comprise these compounds.  
WO/2017/104294A1
The purpose of the present invention is to provide an oxazine compound that is characterized by having a group that has an aromatic ring structure and multiple specified carbon-carbon double bond structures. Further, a composition includ...  
WO/2017/104295A1
The purpose of the present invention is to provide an oxazine compound that is characterized by having a group that has an aromatic ring structure and multiple specified carbon-carbon double bond structures. Further, a composition includ...  
WO/2017/070718A4
The invention provides compounds for use as medicaments, which act by inhibiting CYP17A1 and CYP19A1 enzymes. The compounds have particular application in the treatment of cancer especially prostate cancer and breast cancer. The compound...  
WO/2017/098927A1
The present invention provides an oxazine compound having a specific structure, which is characterized by including a group having: an aromatic ring structure; and a plurality of specified carbon-carbon triple bond structures. The presen...  
WO/2017/093157A1
The present invention relates to compounds of formula I or pharmaceutically acceptable salt, solvate or hydrate thereof wherein ASC is Ring A represents a 4- to 6-membered saturated ring containing carbon atoms as ring members in additio...  
WO/2017/095732A1
Described herein is an unsaturated fluorinated compound of formula (I) where X is O or N; Y is F or H; Z is F or CF3; and A is F or CF3 wherein when X is O, then n is 1, Y is H, Z is F, A is F, and Rf is a linear or branched perfluorinat...  
WO/2017/049245A3
The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions fu...  
WO/2015/111004A3
The present invention relates to an improved process for the preparation of chlorophenyl trifluoroethanone of formula (I), an intermediate used in the preparation of Efavirenz.  
WO/2017/070796A1
The present application relates to novel heterocycle derivatives of Formula (I), to processes for preparing them, pharmaceutical compositions containing them, and their use thereof in the treatment or prevention of acute and/or chronic n...  
WO/2017/070718A1
The invention provides compounds for use as medicaments, which act by inhibiting CYP17A1 and CYP19A1 enzymes. The compounds have particular application in the treatment of cancer especially prostate cancer and breast cancer. The compound...  
WO/2017/066699A1
The invention includes methods and materials for forming and manipulating aromatic-based polymers and copolymers using biomass compounds as starting materials. Embodiments of the invention can be used in processes designed to replace tho...  
WO/2017/064350A1
The invention relates to a new family of six-membered benzo-heterocycles having oxygen and nitrogen atoms, joined to substituted purines, halogens and triazoles which are useful in cancer treatment, in particular in treatments whose ther...  
WO/2017/056115A1
The present invention provides novel N-aryl containing fused heterocyclic compounds as anticancer agents, especially as estrogen receptor (ER) antagonists/ degraders and process for their preparation.  
WO/2017/024229A8
A process for the stereoselective synthesis of chiral 3-heterocyclyl-1,2-dihydroxy cyclohexanes is disclosed. The process involves reacting a tricyclic nitrogenous heterocycle with an allyl carbonate in the presence of a chiral palladium...  
WO/2017/049409A1
Disclosed are compounds of general formula (I) that promote readthrough of a premature termination codon (PTC) of an RNA molecule in a translation system, and their use, alone or in combination with other compounds, such as aminoglycosid...  
WO/2017/049245A2
The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions fu...  
WO/2017/040965A1
A lubricant composition includes a base oil present in an amount of greater than 70 parts by weight per 100 parts by weight of the lubricant composition and an antioxidant. The antioxidant has the structure: wherein each X is independent...  
WO/2017/040963A1
The present invention is directed to compounds of Formula I: and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers or thereof, wherein R1, R2, R2', L, X, W, Y1,Y2, Y3, and Y4 are described herein.  
WO/2017/028940A1
The present invention relates to the compounds of the formula (1) and to organic electroluminescent devices, in particular blue-emitting devices, in which these compounds are used as host material or dopant in the emitting layer and/or a...  
WO/2017/028941A1
The present invention relates to the compounds of the formulae (1) and (2) and to organic electroluminescent devices, in particular blue- emitting devices, in which these compounds are used as host material or dopant in the emitting laye...  
WO/2017/024229A1
A process for the stereoselective synthesis of chiral 3-heterocyclyl-1,2-dihydroxy cyclohexanes is disclosed. The process involves reacting a tricyclic nitrogenous heterocycle with an allyl carbonate in the presence of a chiral palladium...  
WO/2006/105127A8
Compounds, pharmaceutical compositions, kits and methods are provided for use with hydroxysteroid dehydrogenases that comprise a compound selected from the group consisting of: formula (I), wherein the variables are as defined herein.  
WO/2017/018476A1
Provided is a crystal of a quinazoline derivative. The present invention relates to an acid addition salt of a compound represented by formula (I), and a pharmaceutical composition and the like which contain the acid addition salt.  
WO/2017/018751A1
The present invention relates to a novel compound showing leukotriene B4 receptor 2 (BLT2) inhibitory activity and a pharmaceutical composition, for preventing or treating inflammatory diseases, comprising same as an active ingredient. I...  
WO/2017/017505A1
Invention is related to novel compounds – benzenesulfonamides of general formulas (I) and (II). The compounds can be used in biomedicine as active ingredients in pharmaceutical formulations, because they inhibit enzymes which participa...  
WO/2017/018750A1
The present invention relates to a novel compound showing leukotriene B4 receptor 2 (BLT2) inhibitory activity and a pharmaceutical composition, for preventing or treating inflammatory diseases, comprising same as an active ingredient. I...  
WO/2017/014546A1
The present invention relates to a luminescent material for delayed fluorescence and an organic electroluminescent device comprising the same. By using the luminescent material for delayed fluorescence according to the present invention,...  
WO/2017/012890A1
The present invention relates to novel selective 11-beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors and the use thereof to prevent age-induced skin structure and function defects.  
WO/2017/010399A1
Provided are compounds having RORγt inhibitory effects represented by formula (I). Compounds represented by formula (I) (wherein L represents -NR1ACO-, -SO2- or the like, A represents a substituted or unsubstituted aromatic carbocyclic ...  
WO/2016/210134A1
A method of treating cancer in a subject in need thereof includes administering to the subject therapeutically effective amounts of a PP2A activator and a protein kinase inhibitor.  
WO/2016/208775A1
The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep d...  
WO/2016/204276A1
[Problem] To provide a substrate solution for lipase activity measurement, a lipase activity measurement reagent, and an emulsion solution having excellent storage stability. Also to provide a method for measuring the lipase activity in ...  
WO/2016/203773A1
Provided is an electrochromic compound represented by the following general formula (I) or (II) where R1 to R13 are each independently a hydrogen atom, a halogen atom, a monovalent organic group, or a polymerizable functional group, and ...  
WO/2016/197730A1
The present invention relates to an organic electroluminescent material, which has a structure as represented by formula (I). Compounds as represented by formula (I) have highly stable electron acceptor groups and electron donor groups, ...  
WO/2016/201225A1
The invention provides aryl dihydro-2H-benzo[b] [l,4]oxazine sulfonamide and related compounds, pharmaceutical compositions, methods of promoting RORy activity, methods of increasing the amount of IL-17 in a subject, and methods of treat...  
WO/2016/198374A1
Substituted aromatic sulfonamides of formula (I) pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a di...  
WO/2016/198937A1
The present invention relates to compound of formula (I), or stereoisomers and pharmaceutically acceptable salts as muscarinic M1 receptor positive allosteric modulators. This invention also relates to methods of preparing such compounds...  
WO/2016/198691A1
The present invention relates to compounds of formula I or pharmaceutically acceptable salt, solvate or hydrate thereof, wherein ASC is -N(R8)(R9)ASC-1 ASC-1 is Ring A represents a 4- to 6-membered saturated ring containing carbon atoms ...  
WO/2016/180751A1
The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8 and R9 are as described herein, compositions including the compounds and methods of using the compounds.  
WO/2016/181846A1
In order to provide a novel π-conjugated compound capable of increasing the light-emission efficiency of an organic electroluminescence element, for example, this π-conjugated compound has a structure indicated by general formula (1). ...  
WO/2016/173020A1
A conjugated compound containing a diphenyl sulfone phenyl structure, a method for preparing same, and use for fabricating a light emitting layer or an electronic transmission layer of an organic electroluminescent diode. The compound ha...  
WO/2016/161279A1
There are disclosed compounds of formula (I) that modulate or inhibit the enzymatic activity of indoleamine-2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, suc...  
WO/2016/089182A9
The present invention relates to a polybenzoxazine precursor and a method for preparing the same and, more specifically, to a polybenzoxazine precursor and a method for preparing the same, wherein the polybenzoxazine precursor can be pre...  

Matches 151 - 200 out of 6,616